1-(4-Chlorobenzenesulfonyl)-4-(pyridin-2-yl)piperazine

Catalog No. :
ACKXLH194
CAS No. :
333440-99-6
Molecular Formula :
C15H16ClN3O2S
Molecular Weight :
337.83

IUPAC Name:1-((4-chlorophenyl)sulfonyl)-4-(pyridin-2-yl)piperazine

1-(4-Chlorobenzenesulfonyl)-4-(pyridin-2-yl)piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg90%$121.00Login to see priceInquiryInquiry
10mg90%$148.00Login to see priceInquiryInquiry
250mg90%$640.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(4-Chlorobenzenesulfonyl)-4-(pyridin-2-yl)piperazine
IUPAC Name1-((4-chlorophenyl)sulfonyl)-4-(pyridin-2-yl)piperazine
MDL No.MFCD01185728
Molecular FormulaC15H16ClN3O2S
Molecular Weight337.83
SMILESO=S(N1CCN(C2=NC=CC=C2)CC1)(C3=CC=C(Cl)C=C3)=O
InChI KeyOJAKKSSXVSWKKR-UHFFFAOYSA-N
Synonym4-CHLORO-1-((4-(2-PYRIDYL)PIPERAZINYL)SULFONYL)BENZENE;Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-(2-pyridinyl)-
CAS No.333440-99-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACKXLH194 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACUGEK285 route compound structure diagram
    ACUGEK28534803-66-2 In Stock
  4. Then
  5. ACKXLH194 route product structure diagram
    ACKXLH194333440-99-6
Inquiry

2. ACKXLH194 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHPUX913 route compound structure diagram
    ACHPUX91378135-07-6 In Stock
  2. Plus
  3. ACUGEK285 route compound structure diagram
    ACUGEK28534803-66-2 In Stock
  4. Then
  5. ACKXLH194 route product structure diagram
    ACKXLH194333440-99-6
Inquiry

Comments (0)